[HTML][HTML] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
Background Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell …
N Aiko, T Shimokawa, K Miyazaki, Y Misumi, Y Agemi… - BMC cancer, 2018 - Springer
Background Compared with standard chemotherapy, epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs …
MX Li, H He, ZH Ruan, YX Zhu, RQ Li, X He, BH Lan… - BMC cancer, 2017 - Springer
Background Central nervous system (CNS) brain metastasis of advanced non-small cell
lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy …
lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy …
The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
H Bai, B Han - OncoTargets and therapy, 2017 - Taylor & Francis
Brain metastases are usual in non-small-cell lung cancer (NSCLC) with poor prognosis and
few available therapeutic options. This retrospective study aims to evaluate the efficacy of …
few available therapeutic options. This retrospective study aims to evaluate the efficacy of …
A comparison between first-, second-and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer and …
S Caponnetto, O Cantale, A Friedlaender… - Journal of Molecular …, 2021 - mdpi.com
Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …
Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis
Q Zhang, X Zhang, H Yan, B Jiang, C Xu… - Thoracic …, 2016 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI s) are
remarkably effective for treating EGFR‐mutant non‐small cell lung cancer (NSCLC) …
remarkably effective for treating EGFR‐mutant non‐small cell lung cancer (NSCLC) …
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase …
J Kashima, Y Okuma, M Miwa, Y Hosomi - Medical Oncology, 2016 - Springer
Brain metastases (BM) is one of the most crucial distant metastases in patients with non-
small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) …
small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) …
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 …
SJ Park, HT Kim, DH Lee, KP Kim, SW Kim, C Suh… - Lung cancer, 2012 - Elsevier
Non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …
Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-mutant non–small cell lung cancer in patients with brain metastases: the GAP BRAIN open-label …
X Hou, M Li, G Wu, W Feng, J Su, H Jiang… - JAMA Network …, 2023 - jamanetwork.com
Importance Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal
growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) with brain …
growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) with brain …
Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study
Background Non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor
receptor (EGFR) mutations often develop brain metastases. Treatment with EGFR-tyrosine …
receptor (EGFR) mutations often develop brain metastases. Treatment with EGFR-tyrosine …
相关搜索
- gefitinib erlotinib and afatinib
- lung cancer growth factor
- receptor tyrosine growth factor
- afatinib in patients growth factor
- brain metastasis growth factor
- lung cancer egfr tkis
- egfr mutations growth factor
- kinase inhibitors growth factor
- lung cancer brain metastasis
- lung cancer comparison of the efficacies
- comparison of the efficacies growth factor
- brain metastases egfr tkis
- kinase inhibitors brain metastasis
- kinase inhibitors receptor tyrosine
- receptor tyrosine brain metastasis
- brain metastasis either exon